Polyvalent Immunoglobulin as a Potential Treatment Option for Patients with Recurrent COPD Exacerbations

References

• Gold reports for personal use - global initiative for chronic obstructive lung disease - GOLD. Available from: https://goldcopd.org/gold-reports/. Accessed August 5, 2020.
   Google Scholar
• McGhan R, Radcliff T, Fish R, Sutherland ER, Welsh C, Make B. Predictors of rehospitalization and death after a severe exacerbation of COPD. Chest. 2007;132(6):1748–1755. doi:10.1378/chest.06-3018
   PubMed Web of Science ®Google Scholar
• Mittmann N, Kuramoto L, Seung SJ, Haddon JM, Bradley-Kennedy C, Fitzgerald JM. The cost of moderate and severe COPD exacerbations to the Canadian healthcare system. Respir Med. 2008;102(3):413–421.
   PubMed Web of Science ®Google Scholar
• Pocket guide to COPD diagnosis, management, and prevention a guide for health care professionals. 2020. Available from: www.goldcopd.org. Accessed January 13, 2021.
   Google Scholar
• Chapel H, Prevot J, Gaspar HB, et al. Primary immune deficiencies - principles of care. Front Immunol. 2014;5. doi:10.3389/fimmu.2014.00627
   Web of Science ®Google Scholar
• Berger M, Murphy E, Riley P, Bergman GE; Investigators VT. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G. South Med J. 2010;103(9):856–863. doi:10.1097/SMJ.0b013e3181eba6ea
   PubMed Web of Science ®Google Scholar
• Cowan J, Gaudet L, Mulpuru S, et al. A retrospective longitudinal within-subject risk interval analysis of immunoglobulin treatment for recurrent acute exacerbation of chronic obstructive pulmonary disease. PLoS One. 2015;10(11):e0142205. doi:10.1371/journal.pone.0142205
   PubMed Web of Science ®Google Scholar
• McCullagh BN, Comellas AP, Ballas ZK, Newell JD, Zimmerman MB, Azar AE. Antibody deficiency in patients with frequent exacerbations of Chronic Obstructive Pulmonary Disease (COPD). PLoS One. 2017;12(2):e0172437. doi:10.1371/journal.pone.0172437
   PubMed Web of Science ®Google Scholar
• Janeway CA, Travers P, Walport M, Shlomchik MJ. Immunobiology - NCBI Bookshelf. 5th ed. New York: Garland Science; 2001. Available from: https://www.ncbi.nlm.nih.gov/books/NBK10757/. Accessed January 1, 2021.
   Google Scholar
• Mouthon L, Kazatchkine MD. Polyvalent immunoglobulins in human pathology: principles of use and indications. Med Ther. 1997;3(10):863–868.
   Google Scholar
• Novaretti M, Dinardo C. Immunoglobulin: production, mechanisms of action and formulations. Rev Bras Hematol Hemoter. 2011;33(5):377–382. doi:10.5581/1516-8484.20110102
   PubMedGoogle Scholar
• Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. Am J Respir Crit Care Med. 2006;173(10):1114–1121. doi:10.1164/rccm.200506-859OC
   PubMed Web of Science ®Google Scholar
• Robinson P, Anderson D, Brouwers M, Feasby TE, Hume H. Evidence-based guidelines on the use of intravenous immune globulin for hematologic and neurologic conditions. Transfus Med Rev. 2007;21(Suppl–1):S3–S8. doi:10.1016/j.tmrv.2007.01.004
   PubMedGoogle Scholar
• Kumar A, Patwa HS, Nowak RJ. Immunoglobulin therapy in the treatment of multifocal motor neuropathy. J Neurol Sci. 2017;375:190–197. doi:10.1016/j.jns.2017.01.061
   PubMed Web of Science ®Google Scholar
• Hartung H-P, Mouthon L, Ahmed R, Jordan S, Laupland KB, Jolles S. Clinical applications of intravenous immunoglobulins (IVIg) - beyond immunodeficiencies and neurology. Clin Exp Immunol. 2009;158:23–33. doi:10.1111/j.1365-2249.2009.04024.x
   PubMed Web of Science ®Google Scholar
• Edgar JDM, Richter AG, Huissoon AP, et al. Prescribing Immunoglobulin replacement therapy for patients with non-classical and secondary antibody deficiency: an analysis of the practice of clinical immunologists in the UK and Republic of Ireland. J Clin Immunol. 2018;38(2):204–213. doi:10.1007/s10875-017-0469-4
   PubMed Web of Science ®Google Scholar
• Barth J, Jaeger D, Broder M. Is there a benefit of an additive standard immunoglobulin therapy for the clinical course of COPD patients under chronic immunosuppressive therapy? Title. Eur Respir J. 2001;18(Suppl 33):24s.
   Google Scholar
• Leitao Filho FS, Won Ra S, Mattman A, et al. Serum IgG and risk of exacerbations and hospitalizations in chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2017;140(4):1164–1167.e6. doi:10.1016/j.jaci.2017.01.046
   PubMed Web of Science ®Google Scholar
• Holm AM, Andreassen SL, Christensen VL, et al. Hypogammaglobulinemia and risk of exacerbation and mortality in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2020;15:799–807. doi:10.2147/COPD.S236656
   PubMed Web of Science ®Google Scholar
• GOLD 2017 global strategy for the diagnosis, management and prevention of COPD - global initiative for chronic obstructive lung disease - GOLD. Available from: http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/. Accessed July 6, 2017.
   Google Scholar
• Settipane GA, Pudupakkam RK, McGowan JH. Corticosteroid effect on immunoglobulins. J Allergy Clin Immunol. 1978;62(3):162–166. doi:10.1016/0091-6749(78)90101-X
   PubMed Web of Science ®Google Scholar
• Kawano T, Matsuse H, Obase Y, et al. Hypogammaglobulinemia in steroid-dependent asthmatics correlates with the daily dose of oral prednisolone. Int Arch Allergy Immunol. 2002;128(3):240–243.doi:10.1159/000064258
   PubMed Web of Science ®Google Scholar
• Dhalla F, Misbah SA. Secondary antibody deficiencies. Curr Opin Allergy Clin Immunol. 2015;15(6):505–513. doi:10.1097/ACI.0000000000000215
   PubMed Web of Science ®Google Scholar
• Costa-Carvalho BT, Wandalsen GF, Pulici G, Aranda CS, Sole D. Pulmonary complications in patients with antibody deficiency. Allergol Immunopathol (Madr). 2011;39(3):128–132. doi:10.1016/j.aller.2010.12.003
   PubMed Web of Science ®Google Scholar
• Cinetto F, Scarpa R, Rattazzi M, Agostini C. The broad spectrum of lung diseases in primary antibody deficiencies. Eur Respir Rev. 2018;27(149):180019. doi:10.1183/16000617.0019-2018
   PubMed Web of Science ®Google Scholar
• Kherad O, Rutschmann OT. Viral infections as a cause of chronic obstructive pulmonary disease (COPD) exacerbation. Praxis (Bern 1994). 2010;99(4):235–240. doi:10.1024/1661-8157/a000034
   PubMedGoogle Scholar
• Bourbeau J, Bhutani M, Hernandez P, et al. Canadian Thoracic Society Clinical Practice Guideline on pharmacotherapy in patients with COPD – 2019 update of evidence. Can J Respir Crit Care, Sleep Med. 2019;3(4):210–232. doi:10.1080/24745332.2019.1668652
   Web of Science ®Google Scholar
• Kitz R, Ahrens P, Zielen S. Immunoglobulin levels in bronchoalveolar lavage fluid of children with chronic chest disease. Pediatr Pulmonol. 2000;29(6):443–451. doi:10.1002/(SICI)1099-0496(200006)29:6<443::AID-PPUL6>3.0.CO;2-M
   PubMed Web of Science ®Google Scholar
• Reynolds HY. Immunoglobulin G and Its Function in the Human Respiratory Tract. Mayo Clin Proc. 1988;63(2):161–174. doi:10.1016/S0025-6196(12)64949-0
   PubMed Web of Science ®Google Scholar
• Horton RE, Vidarsson G. Antibodies and their receptors: different potential roles in mucosal defense. Front Immunol. 2013;4(JUL). doi:10.3389/fimmu.2013.00200
   PubMed Web of Science ®Google Scholar
• Saeland E, Vidarsson G, Leusen JHW, et al. Central role of complement in passive protection by human IgG1 and IgG2 anti-pneumococcal antibodies in mice. J Immunol. 2003;170(12):6158–6164. doi:10.4049/jimmunol.170.12.6158
   PubMed Web of Science ®Google Scholar
• Charlson ES, Bittinger K, Haas AR, et al. Topographical continuity of bacterial populations in the healthy human respiratory tract. Am J Respir Crit Care Med. 2011;184(8):957–963. doi:10.1164/rccm.201104-0655OC
   PubMed Web of Science ®Google Scholar
• Fong C, Crichton M, Cassidy A, et al. Altered lung microbiota profiles are associated with disease severity, exacerbation frequency and neutrophilic inflammation in bronchiectasis. 2016.
   Google Scholar
• Zhang M, Li Q, Zhang X-Y, Ding X, Zhu D, Zhou X. Relevance of lower airway bacterial colonization, airway inflammation, and pulmonary function in the stable stage of chronic obstructive pulmonary disease. Eur J Clin Microbiol Infect Dis. 2010;29(12):1487–1493. doi:10.1007/s10096-010-1027-7
   PubMed Web of Science ®Google Scholar
• Dickson RP, Erb-Downward JR, Huffnagle GB. The role of the bacterial microbiome in lung disease. Expert Rev Respir Med. 2013;7(3):245–257. doi:10.1586/ers.13.24
   PubMed Web of Science ®Google Scholar
• Tufvesson E, Bjermer L, Ekberg M. Patients with chronic obstructive pulmonary disease and chronically colonized with Haemophilus influenzae during stable disease phase have increased airway inflammation. Int J Chron Obstruct Pulmon Dis. 2015;10:881–889. doi:10.2147/COPD.S78748
   PubMed Web of Science ®Google Scholar
• Murphy TF, Kirkham C, Jones MM, Sethi S, Kong Y, Pettigrew MM. Expression of IgA proteases by haemophilus influenzae in the respiratory tract of adults with chronic obstructive pulmonary disease. J Infect Dis. 2015;212(11):1798–1805. doi:10.1093/infdis/jiv299
   PubMed Web of Science ®Google Scholar
• Wen L, Krauss-Etschmann S, Petersen F, Yu X. Autoantibodies in chronic obstructive pulmonary disease. Front Immunol. 2018;9(JAN):66. doi:10.3389/fimmu.2018.00066
   PubMedGoogle Scholar
• Liang Z, Wang F, Zhang D, et al. Sputum and serum autoantibody profiles and their clinical correlation patterns in COPD patients with and without eosinophilic airway inflammation. J Thorac Dis. 2020;12(6):3085–3100. doi:10.21037/jtd-20-545
   PubMed Web of Science ®Google Scholar
• Negi VS, Elluru S, Sibéril S, et al. Intravenous immunoglobulin: an update on the clinical use and mechanisms of action. J Clin Immunol. 2007;27(3):233–245. doi:10.1007/s10875-007-9088-9
   PubMed Web of Science ®Google Scholar
• Liblau R, Gajdos P, Bustarret FA, El Habib R, Bach JF, Morel E. Intravenous γ-globulin in myasthenia gravis: interaction with anti-acetylcholine receptor autoantibodies. J Clin Immunol. 1991;11(3):128–131. doi:10.1007/BF00918680
   PubMed Web of Science ®Google Scholar
• Sami N, Bhol KC, Ahmed AR. Influence of IVIg therapy on autoantibody titers to desmoglein 1 in patients with pemphigus foliaceus. Clin Immunol. 2002;105(2):192–198. doi:10.1006/clim.2002.5278
   PubMed Web of Science ®Google Scholar